FY2025 · ended Dec 31, 2025 · Revenue $3.02B, +8.0% YoY · Filed Feb 27, 2026
Amneal Pharmaceuticals, Inc. (AMRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.0 billion and net income of $72.1 million. Free cash flow was $269.9 million. As of Jun 30, 2026 it held $127.6 million in cash and investments and $2.6 billion in total debt.
Revenue (TTM)
$3.12B
+9.3% vs year-ago TTM
Net income (TTM)
$157.36M
Operating cash flow (TTM)
$200.78M
-42.8% vs year-ago TTM
Free cash flow (TTM)
$127.83M
-54.8% vs year-ago TTM
EPS (TTM)
$0.48
+4405.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
314.63M
+1.5% vs prior year
Net cash
$-2.44B
as of Jun 30, 2026
Operating margin
14.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AMRX (Nasdaq)
- Fiscal year ends
- December 31
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1723128
- Former names
- Atlas Holdings, Inc. (until Apr 13, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0B | $2.8B | $2.4B | $2.2B | $2.1B |
| Operating income | $394.1M | $249.3M | $204.4M | -$94.9M | $152.7M |
| Net income | $72.1M | — | -$84.0M | -$270.6M | $13.2M |
| Diluted EPS | $0.22 | -$0.38 | -$0.48 | -$0.86 | $0.07 |
| Operating cash flow | $340.0M | $295.1M | $345.6M | $65.1M | $241.8M |
| Free cash flow | $269.9M | $243.2M | $302.4M | $18.7M | $194.1M |
| Total assets | $3.7B | $3.5B | $3.5B | $3.8B | $3.9B |
| Stockholders' equity | -$70.8M | -$109.3M | $19.8M | $298.4M | $360.3M |
| Cash and investments | $282.0M | $110.6M | $91.5M | $26.0M | $247.8M |
| Total debt | $2.7B | $2.5B | $2.5B | $2.7B | $2.8B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 3, 2026 | Nov 3, 2026 |
| 8-K/A | Amended current report | Oct 23, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Unregistered share sale, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jul 31, 2026 | Jul 31, 2026 |
All 694 Amneal Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.